07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

TheraTech, Schwarz Pharma deal

Schwarz acquired exclusive marketing and distribution rights to THRT's Androderm transdermal testosterone patch in Italy, France, the Netherlands, Belgium, Luxembourg, Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Slovakia, Russia and the Ukraine. THRT will...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Androderm testosterone regulatory update

FDA approved 2 and 4 mg doses of transdermal Androderm testosterone for daily use as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. The company plans to...
07:00 , May 16, 2005 |  BioCentury  |  Product Development

Less is more

Now that it has bioavailability data in hand for its Opterone 1% testosterone cream, MacroChem Corp. believes it is positioned to get investors back on board to provide funding to move the product through Phase...
07:00 , May 22, 2000 |  BC Week In Review  |  Company News

Paladin, Watson sales and marketing update

PLB received exclusive Canadian distribution rights to WPI's Androderm testosterone transdermal delivery system to treat male testosterone deficiency. Paladin Labs Inc. (TSE:PLB), Montreal, Quebec   Watson Pharmaceuticals Inc. (WPI), Corona, Calif.   Business: Drug delivery, Metabolic...
07:00 , May 24, 1999 |  BC Week In Review  |  Company News

SmithKline, Watson sales and marketing update

WPI's TheraTech Inc. subsidiary (Salt Lake City, Utah) reacquired from SmithKline all marketing and distribution rights in the U.S. and Canada for TheraTech's Androderm testosterone transdermal system. WPI, which acquired TheraTech last year,...
07:00 , Jul 13, 1998 |  BC Week In Review  |  Company News

TheraTech, Astra AB sales and marketing update

THRT marketing partner Astra launched in Germany a 2.5 mg/day dose of Androderm transdermal testosterone to treat male hypogonadism. TheraTech Inc. (THRT), Salt Lake City, Utah   Astra AB, Sodertalje, Sweden   Business: Metabolic   ...
07:00 , Jul 6, 1998 |  BC Week In Review  |  Clinical News

Androderm testosterone skin patch: Phase II; marketed

A 12-week trial of Androderm showed a 1.34 kg increase in lean body mass compared to no increase with placebo in HIV-infected men, with a greater reduction in fat mass in the treated group versus...
07:00 , Sep 22, 1997 |  BC Week In Review  |  Company News

TheraTech, Astra AB sales and marketing update

Astra received exclusive distribution rights to THRT's Androderm transdermal testosterone system in Germany, Austria and Switzerland. THRT will receive a signing fee, and potentially milestones and royalties, and retains manufacturing rights and certain co-promotion...
07:00 , Jun 16, 1997 |  BC Week In Review  |  Company News

TheraTech, SmithKline sales and marketing update

SmithKline will begin selling THRT's Androderm testosterone transdermal patch in the 5 mg dose size, which was approved for marketing in May. The 5 mg dose allows use of one patch per day...
07:00 , Jun 16, 1997 |  BC Week In Review  |  Clinical News

Androderm testosterone patch data

THRT and marketing partner SmithKline Beecham (Philadelphia, Penn.) presented data from clinical trials of Androderm at the Endocrine Society Meeting in Minneapolis. The 5 mg dose of Androderm applied once per day was found...